|
1.
|
|
7 p, 509.4 KB |
The relationship between jumping to conclusions and social cognition in first-episode psychosis
/
Díaz-Cutraro, L (Universitat Ramon Llull. Departament de Psicologia) ;
López-Carrilero, Raquel (Investigación Biomédica en Red de Salud Mental (CIBERSAM)) ;
García-Mieres, Helena (Investigación Biomédica en Red de Salud Mental (CIBERSAM)) ;
Ferrer-Quintero, Marta (Universitat de Barcelona. Departament de Psicologia Social i Psicologia Quantitativa) ;
Verdaguer-Rodriguez, Marina (Sant Boi de Llobregat. Parc Sanitari Sant Joan de Déu) ;
Barajas Vélez, Ana ;
Grasa, Eva (Institut d'Investigació Biomèdica Sant Pau) ;
Pousa, Esther (Institut d'Investigació Biomèdica Sant Pau) ;
Lorente, Ester (Hospital Clínic Universitari (València)) ;
Barrigón, María Luisa (Universidad Autónoma de Madrid) ;
Ruiz-Delgado, Isabel (Servicio Andaluz de Salud. Unidad de Salud Mental Comunitaria Malaga Norte) ;
González-Higueras, Fermín (Comunidad Terapéutica Jaén Servicio Andaluz de Salud) ;
Cid Colom, Jordi (Institut d'Investigació Biomèdica de Girona) ;
Mas-Expósito, Laia (Associació Centre Higiene Mental Les Corts (Barcelona, Catalunya)) ;
Corripio, Iluminada (Institut d'Investigació Biomèdica Sant Pau) ;
Birulés, Irene (Investigación Biomédica en Red de Salud Mental (CIBERSAM)) ;
Pélaez, Trinidad (Universitat Ramon Llull. Departament de Psicologia) ;
Luengo, Ana (Hospital Clínic Universitari (València)) ;
Beltran, Meritxell (Institut d'Investigació Biomèdica de Girona) ;
Torres-Hernández, Pedro (Comunidad Terapéutica Jaén Servicio Andaluz de Salud, Jaén, Spain) ;
Palma-Sevillano, Carolina (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Moritz, Steffen (University Medical Center Hamburg. Department of Psychiatry and Psychotherapy) ;
Garety, Philippa (King's College London. Institute of Psychiatry, Psychology & Neuroscience) ;
Ochoa, Susana (Investigación Biomédica en Red de Salud Mental (CIBERSAM))
Jumping to conclusions (JTC) and impaired social cognition (SC) affect the decoding, processing, and use of social information by people with psychosis. However, the relationship between them had not been deeply explored within psychosis in general, and in first-episode psychosis (FEP) in particular. [...]
2022 -  10.1038/s41537-022-00221-3
Schizophrenia, Vol. 8 (april 2022)
|
|
|
4.
|
|
11 p, 779.0 KB |
Antitubercular drugs for an old target : GSK693 as a promising InhA direct inhibitor
/
Martínez-Hoyos, María (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Perez-Herran, Esther (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Gulten, Gulcin (Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA) ;
Encinas, Lourdes (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Álvarez-Gómez, Daniel (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Alvarez, Emilio (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ferrer-Bazaga, Santiago (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
García-Pérez, Adolfo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ortega, Fátima (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Angulo-Barturen, Iñigo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Rullas-Trincado, Joaquin (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Blanco Ruano, Delia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Torres, Pedro (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Castañeda, Pablo (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Huss, Sophie (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Fernández Menéndez, Raquel (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
González del Valle, Silvia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Ballell, Lluis (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Barros, David (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Modha, Sundip (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
Dhar, Neeraj (School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne 1015, Switzerland) ;
Signorino-Gelo, François (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
McKinney, John D. (Target and Pathway Validation, Molecular Discovery Research, GlaxoSmithKline, Stevenage, Herts, UK) ;
García-Bustos, Jose Francisco (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Lavandera, Jose Luis (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Sacchettini, James C. (Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA) ;
Jimenez, M. Soledad (Instituto de Salud Carlos III) ;
Martín-Casabona, Nuria (Hospital Universitari Vall d'Hebron) ;
Castro-Pichel, Julia (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Mendoza-Losana, Alfonso (Diseases of the Developing World, GlaxoSmithKline, Severo Ochoa 2, 28760 Tres Cantos, Madrid, Spain) ;
Universitat Autònoma de Barcelona
Despite being one of the first antitubercular agents identified, isoniazid (INH) is still the most prescribed drug for prophylaxis and tuberculosis (TB) treatment and, together with rifampicin, the pillars of current chemotherapy. [...]
2016 - 10.1016/j.ebiom.2016.05.006
EBioMedicine, Vol. 8 (may 2016) , p. 291-301
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
